Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
47 hedge funds and large institutions have $27.2M invested in Infinity Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 9 closing their positions.
8% less funds holding
Funds holding: 51 → 47 (-4)
10% less capital invested
Capital invested by funds: $30.2M → $27.2M (-$3M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$151K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$34.2K |
| 3 |
VF
Virtu Financial
New York
|
+$30.5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$24.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$19.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.56M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$88.7K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$82.7K |
| 4 |
1WA
180 Wealth Advisors
Federal Way,
Washington
|
-$26K |
| 5 |
AC
Athanor Capital
New York
|
-$14K |
INFI Hedge Fund Activity: Q4 2019 in Review
47 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q4 2019, worth a combined $27.2M — down 9.9% from $30.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of INFI and 5 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $151K. The largest seller was Wellington Management Group, exiting entirely with an estimated $1.56M sold.
- 47 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q4 2019, down from 51 in Q3 2019.
- Funds reported $27.2M of Infinity Pharmaceuticals, Inc. stock for Q4 2019, down 9.9% quarter-over-quarter.
- 5 funds opened new Infinity Pharmaceuticals, Inc. positions in Q4 2019 and 9 closed out, a net change of -4 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q4 2019 was Renaissance Technologies, an estimated $151K added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q4 2019 was Wellington Management Group, an estimated $1.56M sold.
Based on aggregated 13F filings for Q4 2019.